Investor Presentation First Nine Months of 2023

51 Investor presentation First nine months of 2023 Novo Nordisk global insulin market leadership at 45.5% and the global insulin volume market declined by 2.8% North America Operations Market growth: -3.7% MS: 37.5% MS gain/loss': -0.7%-p Sales growth: -24% USA Market growth: -3.8% MS: 37.2% MS gain/loss: -0.5%-p Sales growth: -25% Global Market growth: -2.8% MS 45.5% MS gain/loss: -1.3%-p Sales growth: -7% Novo NordiskⓇ International Operations Market growth: -2.5% MS: 48.3% MS gain/loss: -1.6%-p Sales growth: -1% Market growth: -4.2% MS: 58.2% MS gain/loss¹: 1.1%-p Sales growth: 5% Region China Market growth: 1.5% MS: 41.7% MS gain/loss¹: -7.7%-p Sales growth: -10% EMEA Market growth: -3.2% MS: 47.2% ROW MS gain/loss: -0.5%-p Sales growth: 2% Source: IQVIA MAT, Aug 2023 volume figures Note: Sales growth for first nine months of 2023 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with Aug 2022 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; ROW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong; Market values are based on the list prices

View entire presentation